Although PRA is a pharmacological efficacy biomarker for aliskiren and has been considered as an outcome measure in DM, the effects of renin inhibitors on local tissue RAS are not easily demonstrable in clinical studies because there are no available biomarkers for local RAS activation. This evidence concerns the gene REN and diabetes mellitus.